TIL

Companies
NASDAQ
Instil Bio Inc.
Health Care
Price Chart
Overview

About TIL

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Market Cap
$69.6M
Volume
2.2M
Avg. Volume
4.1M
P/E Ratio
-1.3595692
Dividend Yield
0.00%
Employees
192.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.17
Moderate Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for TIL.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, TIL shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$69.6M
Volume2.2M
P/E Ratio-1.36
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025

PortfolioPilot Analysis

Get AI-powered insights on how TIL fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025